

Evolve Formulas Transdermal NanoSerum™ CBD Met with Unprecedented Response across Colorado Market

—Industry-First Formulation Harnesses the Anti-Inflammatory Qualities of CBD and Antioxidant Power of Resveratrol for Maximum Wellness Benefits—

DENVER, Colo.--(BUSINESS WIRE)--November 7, 2018--NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, today announced the expansion of its CBD-dominant product—the Evolve Formulas Transdermal NanoSerum™ CBD with Resveratrol—across Colorado due to considerable public demand. The company has already moved more than 1,000 units in the market in less than a month.

The Evolve Formulas Transdermal NanoSerum™ CBD utilizes a combination formula of synergistic cannabinoids, with each precision-metered dose containing 15mg of CBD and 1.5mg of THC. In addition, the unique, research-backed scientific formulation includes terpenes and resveratrol for maximum therapeutic benefit. Studies show that CBD can aid in relieving inflammation, anxiety, pain and insomnia, while restorative ingredient resveratrol is lauded in the health, wellness and beauty worlds for its antioxidant, neuroprotective, anti-aging and cognitive enhancement benefits. The new item has been met with an overwhelmingly positive response from consumers across the state.

“NanoSphere takes great pride in developing world-class offerings that not only utilize our cutting edge, patented technology, but that include thoughtful formulations with the consumer in mind. Our goal is to deliver unparalleled relief and ensure customers receive the most consistent, trustworthy and effective product possible,” said Robert Sutton, Chairman and CEO of NanoSphere Health Sciences and Evolve Formulas. “Seeing the public’s tremendous response to our CBD-dominant NanoSerum™ has been nothing short of rewarding, motivating us to continue innovating and expanding our industry-leading solutions across the state, country and continent.”

“As a mom of two toddlers, my days are hectic and long, and unwinding at night is a challenge. I am thinking of all the tasks that tomorrow will bring—so getting to sleep has been difficult for me. Now, I use Evolve’s CBD and it’s fantastic. It reduces my stress and anxiety and helps me get a full night’s rest,” said Kelly S., Evolve Formulas customer. “Plus, it’s natural and there are no side effects. Honestly, I don’t think there’s a better product out there for me.”

The Transdermal NanoSerum™ CBD is now available in 40 of the 200 total dispensaries that Evolve Formulas products are currently in across the state, including all Lucy Sky Cannabis Boutique locations. Within the next month, the CBD product is expected to be in all 200 dispensaries.

For more information on Nanosphere Health Sciences, Inc. or to schedule an interview, please contact Gabrielle Wesseldyk at media@nanospherehealth.com or 212-255-0945.

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: <https://www.nanospherehealth.com/licensing/>

About NanoSphere

NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in the creation of the patented NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. Covered by U.S. Patent No. 10,028,919 and U.S. Patent No. 9,925,149, NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. NanoSphere was awarded the 2018 Frost and Sullivan Technology Innovation Award and was recognized by ACQ5 Global Awards as Company of the Year for Nano-Biotechnology, Innovative Company of the Year for Healthcare, and its CEO Robert Sutton was honored as Gamechanger of the Year. For more information on NanoSphere, please visit <http://www.nanospherehealth.com>.

About Evolve Formulas

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit <https://www.evolveformulas.com/>. Follow us on Facebook, Instagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements,

including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

NanoSphere Health Sciences, Inc.

On behalf of the Board

Robert Sutton, 720-520-4282

Chairman and CEO

rsutton@nanospherehealth.com

or

Investor Contact:

Victor Goncalves, 204-997-5517

Executive Vice President

vgoncalves@nanospherehealth.com

or

The Rosen Group

Gabrielle Wesseldyk, 212-255-0945

gabrielle@rosengrouppr.com